INTERCURE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 999.9 ILa | +0.77% |
|
+5.81% | +115.91% |
| Apr. 01 | InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023 | CI |
| Mar. 22 | InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months | CI |
ETFs positioned on InterCure Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.29% | 3 M€ | -35.65% | - | |
| 0.13% | 13 M€ | -.--% |
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +115.91% | 119M | |
| +29.90% | 272M | |
| +44.86% | 261M | |
| +50.00% | 194M | |
| +43.48% | 131M | |
| -28.57% | 121M | |
| -36.75% | 119M | |
| 0.00% | 86.82M | |
| +150.00% | 75.33M | |
| -4.82% | 55.24M |
- Stock Market
- Equities
- INCR Stock
- Funds and ETFs InterCure Ltd.
